Literature DB >> 23371894

Population pharmacokinetic study of memantine: effects of clinical and genetic factors.

Muriel Noetzli1, Monia Guidi, Karsten Ebbing, Stephan Eyer, Laurence Wilhelm, Agnès Michon, Valérie Thomazic, Abdel-Messieh Alnawaqil, Sophie Maurer, Serge Zumbach, Panteleimon Giannakopoulos, Armin von Gunten, Chantal Csajka, Chin B Eap.   

Abstract

BACKGROUND AND
OBJECTIVE: Memantine, a frequently prescribed anti-dementia drug, is mainly eliminated unchanged by the kidneys, partly via tubular secretion. Considerable inter-individual variability in plasma concentrations has been reported. We aimed to investigate clinical and genetic factors influencing memantine disposition.
METHODS: A population pharmacokinetic study was performed including data from 108 patients recruited in a naturalistic setting. Patients were genotyped for common polymorphisms in renal cation transporters (SLC22A1/2/5, SLC47A1, ABCB1) and nuclear receptors (NR1I2, NR1I3, RXR, PPAR) involved in transporter expression.
RESULTS: The average clearance was 5.2 L/h with a 27 % inter-individual variability (percentage coefficient of variation). Glomerular filtration rate (p = 0.007) and sex (p = 0.001) markedly influenced memantine clearance. NR1I2 rs1523130 was identified as the unique significant genetic covariate for memantine clearance (p = 0.006), with carriers of the NR1I2 rs1523130 CT/TT genotypes presenting a 16 % slower memantine elimination than carriers of the CC genotype.
CONCLUSION: The better understanding of inter-individual variability of memantine disposition might be beneficial in the context of individual dose optimization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23371894     DOI: 10.1007/s40262-013-0032-2

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  41 in total

1.  Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels.

Authors:  A L Slitt; N J Cherrington; D P Hartley; T M Leazer; C D Klaassen
Journal:  Drug Metab Dispos       Date:  2002-02       Impact factor: 3.922

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

3.  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Authors:  M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2009-06-17       Impact factor: 6.875

4.  Current understanding of the pharmacogenomics of metformin.

Authors:  O Zolk
Journal:  Clin Pharmacol Ther       Date:  2009-12       Impact factor: 6.875

5.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

6.  Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring.

Authors:  Muriel Noetzli; Eva Choong; Nicolas Ansermot; Chin B Eap
Journal:  Ther Drug Monit       Date:  2011-04       Impact factor: 3.681

7.  ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

Authors:  Rubin Lubomirov; Julia di Iulio; Aurélie Fayet; Sara Colombo; Raquel Martinez; Catia Marzolini; Hansjakob Furrer; Pietro Vernazza; Alexandra Calmy; Matthias Cavassini; Bruno Ledergerber; Katharina Rentsch; Patrick Descombes; Thierry Buclin; Laurent A Decosterd; Chantal Csajka; Amalio Telenti
Journal:  Pharmacogenet Genomics       Date:  2010-04       Impact factor: 2.089

8.  Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.

Authors:  Maya K Leabman; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Douglas Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Andrew G Clark; Ira Herskowitz; Kathleen M Giacomini
Journal:  Pharmacogenetics       Date:  2002-07

9.  Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine.

Authors:  A E Busch; U Karbach; D Miska; V Gorboulev; A Akhoundova; C Volk; P Arndt; J C Ulzheimer; M S Sonders; C Baumann; S Waldegger; F Lang; H Koepsell
Journal:  Mol Pharmacol       Date:  1998-08       Impact factor: 4.436

10.  Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Authors:  Kathrin Klein; Stefan Winter; Miia Turpeinen; Matthias Schwab; Ulrich M Zanger
Journal:  Front Pharmacol       Date:  2010-11-02       Impact factor: 5.810

View more
  10 in total

Review 1.  Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.

Authors:  Ramon Cacabelos
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

2.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

3.  A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.

Authors:  Rosemary Kanasty; Susan Low; Nupura Bhise; Jung Yang; Erick Peeke; Marlene Schwarz; James Wright; Bennett Carter; Saumya Moorthy; Tyler Grant; Ben DeBenedictis; Megan Bishoff; Craig Simses; Andrew M Bellinger
Journal:  J Control Release       Date:  2019-03-27       Impact factor: 9.776

4.  Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Methods Mol Biol       Date:  2022

5.  Pharmacogenetics of Donepezil and Memantine in Healthy Subjects.

Authors:  María C Ovejero-Benito; Dolores Ochoa; Teresa Enrique-Benedito; Miriam Del Peso-Casado; Pablo Zubiaur; Marcos Navares; Manuel Román; Francisco Abad-Santos
Journal:  J Pers Med       Date:  2022-05-13

6.  Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.

Authors:  Jayashri Kulkarni; Natalie Thomas; Abdul-Rahman Hudaib; Emorfia Gavrilidis; Jasmin Grigg; Raelene Tan; Jacinta Cheng; Amelia Arnold; Caroline Gurvich
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 7.  Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.

Authors:  Muriel Noetzli; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

8.  Dextromethorphan and memantine after ketamine analgesia: a randomized control trial.

Authors:  Elodie Martin; Marc Sorel; Véronique Morel; Fabienne Marcaillou; Pascale Picard; Noémie Delage; Florence Tiberghien; Marie-Christine Crosmary; Mitra Najjar; Renato Colamarino; Christelle Créach; Béatrice Lietar; Géraldine Brumauld de Montgazon; Anne Margot-Duclot; Marie-Anne Loriot; Céline Narjoz; Céline Lambert; Bruno Pereira; Gisèle Pickering
Journal:  Drug Des Devel Ther       Date:  2019-08-02       Impact factor: 4.162

9.  Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan.

Authors:  Takashi Matsumoto; Kyoji Sekiguchi; Zenji Kawakami; Junko Watanabe; Kazushige Mizoguchi; Yasushi Ikarashi; Masahiro Yamamoto
Journal:  Molecules       Date:  2018-12-29       Impact factor: 4.411

Review 10.  Personalized Management and Treatment of Alzheimer's Disease.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Life (Basel)       Date:  2022-03-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.